ARROWg+ard® Antimicrobial Technology

ARROWg+ard is a chlorhexidine-based technology impregnated into the catheter surface.

Chlorhexidine/silver sulfadiazine antimicrobial catheters such as ARROWg+ard are a CDC 1A recommendation for the prevention of catheter-related bloodstream infection.1 ARROWg+ard's ability to save lives and reduce costs by reducing infection has been supported by more than 30 studies.2 No other company's catheter has such a strong track record, or broad-spectrum activity.

  • Maki et al. found ARROWg+ard reduces bacterial colonization of the catheter by 44 percent and catheter-related bacteremia by an even greater 79 percent.3
  • ARROWg+ard has been shown to be effective against the pathogens responsible for CLABSI (see chart below). This includes a wide array of gram-positive bacteria, including S. epidermidis, MRSA and S. aureus; gram-negative bacteria, including Enterococci and Pseudomonas strains; and fungi, including C. albicans.6

Protection Against the Causes of CLABSI

ORGANISM5

PATHOGEN

% OF ALL CLABSI

PROVEN EFFECTIVE IN VITRO6*

Gram-positive

CoNS
Enterococcus species
Staphylococcus aureus

34.1%
16.0%
9.9%



Gram-negative

Klebsiella species
Enterobacter species
Pseudomonas aeruginosa
Escherichia coli
Acinetobacter baumannii

5.8%
3.9%
3.1%
2.7%
2.2%





Fungi

Candida species

11.8%

Total

89.5%

  • Studies were done using ARROWg+ard Blue Plus catheters using In-Vitro zone of inhibition test. ARROWg+ard Blue Plus catheters showed a minimum of a 4 mm zone of inhibition at day seven.

Proven protection, inside and out


ARROWg+ard Blue PLUS® catheters are protected both inside and out (including extension lines and hubs). Chlorhexidine preps the subcutaneous catheter tract and kills organisms in places that you can't reach. ARROWg+ard Blue PLUS also protects the catheter hub and extension lines where competitor catheters do not.

Mark E. Rupp, MD, et al., has conclusively proven the efficacy of ARROWg+ard Blue PLUS catheters to prevent catheter colonization compared with unprotected catheters.4

For more information of clinical studies and research regarding ARROWg+ard® click on the link below:

Clinical Studies and Research

References:

  1.  O'grady, N.P., Alexander, M., Burns L.A., Dellinger, P., Garland, J., Heard, S.O., Lipsett P.A., Masur, H., Mermel, L.A., Pearson, M.L., Raad, I.I., Randolph, A, Rupp, M.E., Saint, S., Guidelines for the Prevention of Intravascular Catheter-Related Infections, 2011. The Centers for Disease Control. http://www.cdc.gov/hicpac/pdf/guidelines/bsi-guidelines-2011.pdf. Accessed May 16, 2011.
  2. http://www.arrowintl.com/documents/pdf/literature/2008-0114.pdf
  3. Maki, D.G., Stolz, S.M., Wheeler, S., Mermel, L.A. Prevention of Central Venous Catheter-Related Bloodstream Infection With an Antiseptic-Impregnated Catheter: A Randomized, Controlled Trial. Annals of Internal Medicine, August 15, 1997, Vol. 127, Issue 4, pp. 257–266.
  4. Rupp, M.E., Lisco, S.J., Lipsett, P.A., Perl, T.M., Keating, K., Civetta, J.M., Mermel, L.A., Lee, D., Dellinger, P.E., Donahue, M., Giles, D., Pfaller, M.A., Maki, D.G., Sherertz, R. Effect of a Second-Generation Venous Catheter Impregnated With Chlorhexidine and Silver Sulfadiazine on Central Catheter-Related Infections: A Randomized, Controlled Trial. Annals of Internal Medicine, Vol. 143, No. 8, October 18, 2005, pp. 570–581.
  5. Hidron AI et al. "Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007." Infection Control and Hospital Epidemiology 2008 Vol 29, No. 11: 996-1011
  6. Data on File
Arrowg+ard and ARROWg+ard Blue Plus are trademarks or registered trademarks of Teleflex Incorporated or its affiliates.